Day: January 15, 2024

Uponor Corporation, Stock Exchange Release, 15 January 2024 at 08:55 EET Uponor Corporation: Cancellation of treasury shares registered The Board of Directors of Uponor Corporation has decided to cancel a total of 373,685 treasury shares. The cancellation of the treasury shares has been registered with the Trade Register maintained by the Finnish Patent and Registration Office today, 15 January 2024. Prior to the cancellation of the treasury shares, the total number of shares in Uponor Corporation was 73,206,944. After the cancellation, the total number of shares in Uponor Corporation is 72,833,259 and the total number of votes attached to the shares is 72,833,259. After the cancellation, Uponor Corporation does not hold any shares in the Company. The cancellation of treasury sales has no effect on the share capital of Uponor Corporation. Further...

VANCOUVER, Canada, Jan. 15, 2024 (GLOBE NEWSWIRE) — Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is proud to introduce Sirona LaboratoriesTM – a wholly-owned subsidiary dedicated to maximizing the commercial potential of its breakthrough anti-aging skincare ingredient, GlycoProteMimTM. Dr. Howard Verrico, CEO and founder of Sirona Biochem, expressed his enthusiasm for the major milestone, stating that the establishment of Sirona Laboratories is meant to not just shape the future of the company, but to revolutionize the global anti-aging skincare market. The announcement follows the recent decision to trademark GlycoProteMim. The extraordinary results from the active ingredient’s clinical trials prompted the company’s strategic decision to establish Sirona Laboratories, which will redefine its trajectory in the...

Multitude’s 3rd Annual “Charity of Your Choice” Initiative Achieves Milestone, Contributing a total of EUR 71,350 to Inspire Giving and Impactful Change Helsinki, 15 January 2024 – Multitude SE – a fully regulated international growth platform for financial technology (ISIN: FI4000106299, WKN: A1W9NS) (“Multitude” or “the Group”) proudly announces the successful conclusion of its 3rd annual “Charity of Your Choice” initiative, following a robust voting process, where employees from over 25 global locations nominated 50 charitable organisations, resulting in a donation of over EUR 17,000 in 2023. The initiative’s unique aspect is the engaging pitch sessions, where employees advocate for their chosen charities by casting a live-vote during one of the company’s All Staff gatherings,...

Oslo, 15 January 2024 – DNO ASA, the Norwegian oil and gas operator, will publish its Q4 2023 operating and interim financial results on 8 February at 07:00 (CET). A videoconference call with executive management will follow at 14:00 (CET). The Company issues below an update on production and sales volumes for the quarter as well as other key financial information that will be further discussed in the earnings call.Volumes (boepd)Gross operated production Q4 2023 Q3 2023 Q4 2022Kurdistan 65,773 25,984 107,822North Sea – – –       Net entitlement production Q4 2023 Q3 2023 Q4 2022Kurdistan 26,057 9,897 25,618North Sea 16,879 14,288 14,976       Sales Q4 2023 Q3 2023 Q4 2022Kurdistan 26,057 9,897 25,618North Sea 15,628 15,749 15,152       Equity accounted production (net) Q4 2023 Q3...

AGAMREE® is the only approved medication in the European Union (EU) for treating all patients from age 4 years with DMD, and the first DMD treatment approved across the U.S., EU and UK This marks the first commercial launch of AGAMREE® globallyPratteln, Switzerland, January 15, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the launch of AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients 4 years of age and older, irrespective of the underlying mutation and ambulatory status, in Germany. AGAMREE® is the first and only medicinal product for DMD to have received full approval in the EU and, following approval in the U.S. last October and in the UK last week, it is the first authorized treatment for patients with the disease in all three territories. “We are very happy that AGAMREE is now commercially...

 PRESS RELEASE – REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, January 15, 2024, 7am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received transparency notifications from François Rieger that can be consulted on the website of BioSenic, under the heading “Major shareholders & transparency notices”. The transparency notification indicates that the shareholdings held by François Rieger have crossed below the threshold of 15% as a result of a share lending on 10 January 2024.  The notification received from François Rieger dated 12 January 2024 contains the following information:Reason for the notification:Passive crossing...

PRESS RELEASE – INSIDE INFORMATION BioSenic reaches agreement on a binding term sheet with Phebra PTY Ltd. with respect to the development of the first oral formulation of arsenic troxide for cGvHD treatment A new binding term sheet has been signed to adapt the terms of two previous agreements under which Phebra granted Medsenic SAS, a subsidiary of BioSenic SA, an exclusive worldwide license agreement with a first marketing and distribution agreement (MDA) for OATO (oral arsenic trioxide) in the field of several targeted autoimmune diseases. Mont-Saint-Guibert, Belgium, January 15, 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, and its subsidiary Medsenic SAS, today announce the signature of a binding term sheet...

– Top Schneider Electric executives attending World Economic Forum annual gathering. – Sustainability and energy resilience at the top of the corporate and public policy agenda. Far greater deployment of existing technologies is needed to keep climate change from spiraling out of control, Schneider Electric, the leader in the digital transformation of energy management and automation, urged today. Accelerating climate change, geopolitical tensions, see-sawing energy prices, and pressure from stakeholders to address these risks, have pushed environmental sustainability and energy resilience to the top of the corporate and policy agenda in recent years. They form the backdrop to the World Economic Forum’s annual meeting in Davos, Switzerland, from 15-19 January, which several senior Schneider Electric executives are attending. “With...

Novel class of antibiotics Bactericidal activity demonstrated in vitro and in vivo against broad range of Gram-negative bacteria, including multidrug-resistant strainsAllschwil, Switzerland, January 15, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement with Spexis AG (SIX: SPEX) for a preclinical program of antibiotics from a novel class, targeting Gram-negative bacteria, including multidrug-resistant strains.1 Dr. Laurenz Kellenberger, Chief Scientific Officer of Basilea, said: “The acquired antibiotics are of a novel class, targeting the lipopolysaccharide transport in Gram-negative bacteria, which have been highlighted by the...